Thermo Fisher Scientific Inc. (TMO)
Analysis of Revenues
Revenue Recognition Accounting Policy
Prior to 2018, Thermo Fisher recognized revenue after all significant obligations had been met, collectability was probable and title had passed, which typically occurred upon shipment, delivery, completion of services, or ratably over the contract period. Beginning in 2018, Thermo Fisher recognizes revenue for the transfer of promised goods or services to customers in an amount that reflects the consideration to which Thermo Fisher expects to be entitled in exchange for those goods or services.
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues (clinical trial logistics, pharmaceutical development and manufacturing services, asset management, diagnostic testing, training, service contracts, and field services including related time and materials) are recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, Thermo Fisher generally uses costs accumulated as inputs to measure progress. For contracts that contain multiple performance obligations, Thermo Fisher allocates the consideration to which it expects to be entitled to each performance obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual performance obligation is transferred to customers. Thermo Fisher exercises judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. Thermo Fisher immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Payments from customers for most instruments, consumables and services are typically due in a fixed number of days after shipment or delivery of the product. Service arrangements commonly call for payments in advance of performing the work (e.g. extended service contracts), upon completion of the service (e.g. pharmaceutical development and manufacturing) or a mix of both.
Source: 10-K (filing date: 2019-02-27).
Revenues as Reported
Thermo Fisher Scientific Inc., Income Statement, Revenues
USD $ in millions
|12 months ended||Dec 31, 2018||Dec 31, 2017||Dec 31, 2016||Dec 31, 2015||Dec 31, 2014|
|Life Sciences Solutions||6,269||5,728||4,978||4,439||4,196|
|Laboratory Products and Services||10,035||7,825||7,030||6,662||6,602|
|Consolidated revenues||Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).||Thermo Fisher Scientific Inc.’s consolidated revenues increased from 2016 to 2017 and from 2017 to 2018.|